Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681233 · ClinicalTrials.gov registry record · NA
Feasibility Study of CBCT for IGRT in Cancer Patients
A NA study of Breast Cancer and Liver Cancer, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT06681233 is a NA study of Breast Cancer and Liver Cancer that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT06681233, a NA study of Breast Cancer and Liver Cancer, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow. Varian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image. This study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments. The goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.
Conditions Studied
Interventions
- DEVICE Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
Study Locations (4)
Ohio
- James Outpatient Center - Columbus
- Ohio State University, Brain and Spine Hospital - Columbus
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute - Columbus
- Stefanie Spielman Comprehensive Breast Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06681233
The ClinicalTrials.gov registry entry for NCT06681233 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Comparison of HyperSight CBCT imaging to conventional CBCT imaging. is the first listed.
NCT06681233 reports 4 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06681233 about?
NCT06681233 is a clinical study titled "Feasibility Study of CBCT for IGRT in Cancer Patients". Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefac...
What is the current status of trial NCT06681233?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-02-19. Estimated completion is 2026-09.
What conditions does trial NCT06681233 study?
This clinical trial studies the following conditions: Breast Cancer, Liver Cancer, Head and Neck Cancers, Gastrointestinal Cancers, Genito Urinary Cancer.
What interventions are being tested in trial NCT06681233?
The interventions under investigation include: Comparison of HyperSight CBCT imaging to conventional CBCT imaging. (DEVICE).
Who is sponsoring clinical trial NCT06681233?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06681233 being conducted?
This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.